Last reviewed · How we verify
ABY-029
At a glance
| Generic name | ABY-029 |
|---|---|
| Also known as | ABY-029 trifluoroacetate salt, IRDye® 800CW Maleimide labeled Affibody peptide |
| Sponsor | Dartmouth-Hitchcock Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- ABY-029 Glioma Trial (PHASE1)
- ABY-029 Head & Neck Trial (PHASE1)
- A Microdose Evaluation Study of ABY-029 in Recurrent Glioma (EARLY_PHASE1)
- A Microdose Evaluation Study of ABY-029 in Head and Neck Oncology Surgery (EARLY_PHASE1)
- A Microdose Evaluation Study of ABY-029 in Primary Sarcoma (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |